MGX
Metagenomi Therapeutics, Inc.
$1.24
+0.00 (+0.00%)
At close · Jul 17
Market Cap
$46.68M
Shares
37,646,858
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.24
Open$1.25
Day$1.22–1.26
52W$1.13–3.95
Avg vol 30d176K
Short int1.7M · 4.5% float · 11.6d
Short vol50%
Last earningsNov 12, 2025
DataFeb 2024–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−3%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−27%
trailing
YTD return
−23%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 48 funds reported for Jun 30 · net +72.1K sh shares · +1 new
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
4.47% of float · ▼ -4.1% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 2-yr low, contrarian setup
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
0%
Y/Y
Free cash flow
$-89.5M
Balance sheet
$41.7M
net cash
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 48 funds reported for Jun 30 · net +72.1K sh shares · +1 new
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
4.47% of float · ▼ -4.1% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
48 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $1 · 4%
52-wk high $4
vs 200-day avg -26%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGX
this stock
Metagenomi Therapeutics, Inc.
|
$46.68M | -23.5% | +16.8% | — | 4.5% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGX | -2.4% | +5.1% | -26.6% | +4.2% | -23.5% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -0.8% | +4.8% | -34.5% | +4.7% | -32.5% |